Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer

AACR Annual Meeting 2022

Published: 14 Apr 2022

Views: 112

Rating:

Save

Prof Benoit You - Hospices Civils de Lyon, Lyon, France

Prof Benoit You speaks to ecancer about the ENDOLA trial that he presented at AACR 2022. This was a phase I/II trial which assessed the safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients.

The phase I trial was charged with determining the safety of the combination with Prof You reporting that it was well tolerated.

He also reports that the phase II trial efficacy data proved promising activity in this combination.

Related Videos

ESMO 2025: Latest developments in endometrial cancer

Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth

ESMO 2025: Latest developments in endometrial cancer ( Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours

Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Dr Mary McCormack - University College Hospital, London, UK

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )

More from ecancer